Successful Ventures invierte en Devicare. La red de Business Angels liderada por Fran Piera, Ot Vila y Dani Romy, que actualmente cuenta con más de 100 inversores activos y que en 2019 invirtió 1,8 MM € en 15 startups de base tecnológica, comienza su andadura en el sector e-health de la mano de la empresa…
The results show the efficacy and tolerance of its products Lit-Control® pH Up and Lit-Control® pH Down to regulate urinary pH in patients with renal lithiasis. The study confirms that maintaining urinary pH within the appropriate range (between 5.5 and 6.2 pH) decreases the likelihood of new events related to kidney stones from appearing by more than 50%.
The Microelectronic Institute of Barcelona-National Microelectronic Centre (IMB-CNM), one of Devicare's leading suppliers, has successfully passed an inspection of its facilities by the Spanish Agency of Medicines and Medical Devices (AEMPS). The ICB-CNM is now accredited as an authorised sub-contractor by the AEMPS to carry out its activity in the medical devices sector.
Devicare, with headquarters in the UAB Research Park, has recently announced business agreements in United States, United Kingdom, Malta and Algeria and is now present in 34 countries. The company has 5 products on the market (a medical device and dietary supplements), 49 patents, 6 clinical trials and 9 scientific publications.
Devicare participated in the National Meeting of the Lithiasis, Endourology, Laparoscopy and Robotics Groups (LELR), held on 24 and 25 January in Palma de Mallorca. The plenary sessions focused on the medical and surgical handling of urinary lithiasis which affects 10% of the Spanish population. The final results of the “Double J” clinical trial led by specialists from nine leading Spanish hospitals renowned for urology care and sponsored by Devicare were also presented during the event.
Dr Carlos Torrecilla, director of the Lithiasis Unit of the Bellvitge University Hospital and national coordinator of the Lithiasis and Endourology Group of the Spanish Association of Urology, is the principal investigator of a clinical trial sponsored by Devicare conducted in nine Spanish university hospitals (Bellvitge, La Paz, Río Hortega, Puigvert Foundation, San Cecilio, Valme, Álvaro Cunqueiro, La Fe and Santiago de Compostela)...
The multinational company Exeltis and the digital therapeutics company Devicare have signed an agreement to market the Lit-Control® family of products in Spain. Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment. This collaboration brings together Exeltis' expertise and excellence in health care with Devicare's experience in product development, intellectual property and clinical research...
Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to evaluate the combined use of a medical device and a nutraceutical in controlling urinary pH and inhibiting crystallisation in order to prevent the calcification of double J stent catheters and reduce the number of associated complications.
The prestigious urologists Manoj Monga of the Cleveland Clinic and Olivier Traxer of the Sorbonne and Pierre and Marie Curie University are organising the first The Talents (The Trans-Atlantic Leaders in Endourological Technologies) symposium, from 5 to 7 April in Paris, in order to build bridges between young European and North American leaders in the field of endourology.
The 33rd European Urology Congress (EAU 2018) closed its doors yesterday in Copenhagen with excellent figures: 15,000 urologists, 160 companies and 2,000 business representatives. Devicare has been present in the exhibition area together with one of its international partners presenting Lit-Control®, the first medical solution which allows recurrent urinary diseases to be effectively addressed with an innovative solution enabling patients to check their own urinary pH with remote monitoring.
Board Member and Private Investor in different biotech start-ups.
Former President of Medical Devices Committee at Catalonia Association of Biotech Companies.
Master in Business Administration.
Master in International Business.
Master in Entrepreneurship & Innovation.
BSc. Industrial Engineering.
BSc. Electronic Engineering.
+10 years of experience in Business Development in MD companies.
QMS Manager at Mesoestetic.
Deputy Quality Manager at SANJO.
PDD at IESE.
Master in Business Administration.
BSc in Chemical Engineering.
+15 years of experience managing QA and QC in different industrial companies (pharma and automotive sectors)
Marketing Director at Rubió.
Marketing Director at Lacer.
Master in Business Administration.
BSc in Law.
+25 years in strategic marketing positions managing budgets +€20 M, sales force +300 representatives, and having launched +10 products to the market in Urology and Cardiology.
+15 Years of experience in strategic positions regarding prototype and production in prestigious companies as Sanyo or Ateknea. Master’s in production management. BSc Electronic Engineering.
Scientific Director at AB-Biotics
PhD in Microbiology
BSc in Food Science and Technology
BSc in Biology
+15 years of experience in strategic research positions managing the development of innovative nutraceuticals and monitoring clinical trials
Financial Director at Medichem.
Financial Director at Combino.
Master in Financial Management.
BSc in Business Administration.
+20 years of experience in strategic financial positions managing budgets of +€80 M, investments of +€50 M and being in charge of the M&A of Combino by Medichem Group.
System Manager at Ficosa.
R&D Manager at FTE Maximal.
R&D Manager at SANYO.
Master in Project Management.
BSc in Telecom. Engineering.
+20 years of experience in strategic R&D positions managing the development of successful products and creating R&D teams from scratch to +120 people.